Carfilzomib for relapsed and refractory multiple myeloma

References

• KumarSKDispenzieriALacyMQContinued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia20142851122112824157580
   PubMed Web of Science ®Google Scholar
• KumarSKDimopoulosMAKastritisENatural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyLeukemia201731112443244828620163
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• DemoSDKirkCJAujayMAAntitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res200767136383639117616698
   PubMed Web of Science ®Google Scholar
• LeleuXMartinTGEinseleHRole of proteasome inhibitors in relapsed and/or refractory multiple myelomaClin Lymphoma Myeloma Leuk201819192230287200
   PubMed Web of Science ®Google Scholar
• Guerrero-GarciaTAGandolfiSLaubachJPThe power of proteasome inhibition in multiple myelomaExpert Rev Proteomics201815121033105230427223
   PubMed Web of Science ®Google Scholar
• AdamsJThe proteasome: a suitable antineoplastic targetNat Rev Cancer20044534936015122206
   PubMed Web of Science ®Google Scholar
• NiewerthDJansenGAssarafYGZweegmanSKaspersGJLCloosJMolecular basis of resistance to proteasome inhibitors in hematological malignanciesDrug Resist Updat201518183525670156
   PubMed Web of Science ®Google Scholar
• KuhnDJChenQVoorheesPMPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood200711093281329017591945
   PubMed Web of Science ®Google Scholar
• ParlatiFLeeSJAujayMCarfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasomeBlood2009114163439344719671918
   PubMed Web of Science ®Google Scholar
• Arastu-KapurSAnderlJLKrausMNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsClin Cancer Res20111792734274321364033
   PubMed Web of Science ®Google Scholar
• YangJWangZFangYPharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in ratsDrug Metab Dispos201139101873188221752943
   PubMed Web of Science ®Google Scholar
• MoreauPMateosMVBerensonJROnce weekly versus twice Weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyThe Lancet Oncol201819795396429866475
   PubMed Web of Science ®Google Scholar
• O’ConnorOAStewartAKValloneMA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesClin Cancer Res200915227085709119903785
   PubMed Web of Science ®Google Scholar
• AlsinaMTrudelSFurmanRRA phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaClin Cancer Res201218174830484022761464
   PubMed Web of Science ®Google Scholar
• SiegelDSMartinTWangMA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood2012120142817282522833546
   PubMed Web of Science ®Google Scholar
• VijRWangMKaufmanJLAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomibnaive patients with relapsed and/or refractory multiple myelomaBlood2012119245661567022555973
   PubMed Web of Science ®Google Scholar
• VijRSiegelDSJagannathSAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibBr J Haematol2012158673974822845873
   PubMed Web of Science ®Google Scholar
• BadrosAZVijRMartinTCarfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia20132781707171423364621
   PubMed Web of Science ®Google Scholar
• HájekRMassziTPetrucciMTA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophospha-mide in relapsed and refractory multiple myeloma (Focus)Leukemia201731110711427416912
   PubMed Web of Science ®Google Scholar
• PapadopoulosKPSiegelDSVesoleDHPhase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myelomaJ Clin Oncol201533773273925225420
   PubMed Web of Science ®Google Scholar
• LendvaiNHildenPDevlinSA phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myelomaBlood2014124689990624963043
   PubMed Web of Science ®Google Scholar
• DimopoulosMAGoldschmidtHNiesvizkyRCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (endeavor): an interim overall survival analysis of an open-label, randomised, phase 3 trialLancet Oncol201718101327133728843768
   PubMed Web of Science ®Google Scholar
• DimopoulosMAMoreauPPalumboAENDEAVOR InvestigatorsCarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (endeavor): a randomised, phase 3, open-label, multicentre studyLancet Oncol2016171273826671818
   PubMed Web of Science ®Google Scholar
• NiesvizkyRMartinTGBensingerWIIIPhase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaClin Cancer Res20131982248225623447001
   PubMed Web of Science ®Google Scholar
• WangMMartinTBensingerWPhase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood2013122183122312824014245
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMAASPIRE InvestigatorsCarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• SiegelDSDimopoulosMALudwigHImprovement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myelomaJ Clin Oncol201836872873429341834
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPGAndersonKCMechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myelomaMol Cancer Ther201110112034204222072815
   PubMed Web of Science ®Google Scholar
• BerdejaJGHartLLMaceJRPhase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myelomaHaematologica2015100567067625710456
   PubMed Web of Science ®Google Scholar
• KaufmanJLZimmermanTRosenbaumCAPhase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a multiple myeloma research Consortium (MMRC) clinical trialBlood20141242132
   Web of Science ®Google Scholar
• VesoleDHBilottiERichterJRPhase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myelomaBr J Haematol20151711525926018491
   PubMed Web of Science ®Google Scholar
• ShahJJStadtmauerEAAbonourRCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myelomaBlood2015126202284229026384354
   PubMed Web of Science ®Google Scholar
• ChariALarsonSHolkovaBPhase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myelomaLeuk Lymphoma201859112588259429616843
   PubMed Web of Science ®Google Scholar
• ChariAGirniusSChhabraSInitial phase 2 results of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaBlood2017130Suppl 13111
   Google Scholar
• ChariARichterJRShahNPhase I-B study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM)J Clin Oncol20183615_suppl8014
   Google Scholar
• ChariAMartinez-LopezJMateosMVDaratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001J Clin Oncol20183615_suppl8002
   Web of Science ®Google Scholar
• BerensonJRCartmellABessudoACHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaBlood2016127263360336827207788
   PubMed Web of Science ®Google Scholar
• SiegelDMartinTNookaAIntegrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica201398111753176123935022
   PubMed Web of Science ®Google Scholar
• Chen-ScarabelliCCorsettiGPasiniESpasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivityEBioMedicine20172120621228587834
   PubMed Web of Science ®Google Scholar
• FuHYMinaminoTTsukamotoOOverexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibitionCardiovasc Res200879460061018508854
   PubMed Web of Science ®Google Scholar
• AtrashSTullosAPanozzoSCardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibBlood Cancer J201551e27225594159
   PubMedGoogle Scholar
• LandJAfifiSAdelNGIncidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at Memorial Sloan Kettering cancer centerBlood2015126234265
   Web of Science ®Google Scholar
• DimopoulosMARoussouMGavriatopoulouMCardiac and renal complications of carfilzomib in patients with multiple myelomaBlood Adv20171744945429296960
   PubMed Web of Science ®Google Scholar
• RosenthalALuthiJBelohlavekMCarfilzomib and the cardiorenal system in myeloma: an endothelial effect?Blood Cancer J201661e38426771810
   PubMedGoogle Scholar
• LaroccaADoldSMZweegmanSPatient-centered practice in elderly myeloma patients: an overview and consensus from the European myeloma network (EMN)Leukemia20183281697171229880892
   PubMed Web of Science ®Google Scholar
• MartinTGMannisGIIIChariAMunsterPCampanaFHuiAPhase Ib study of Isatuximab and carfilzomib in relapse and refractory multiple myelomaBlood201612822211127789435
   PubMed Web of Science ®Google Scholar